Infliximab for the treatment of hidradenitis suppurativa
- 30 November 2003
- journal article
- case report
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 49 (5), 275-276
- https://doi.org/10.1016/s0190-9622(03)01132-0
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximabJournal of the American Academy of Dermatology, 2002
- Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysisBritish Journal of Dermatology, 2002
- Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease1Transplantation, 2002
- Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor α antagonist etanerceptJournal of the American Academy of Dermatology, 2002
- Infliximab in patients with primary Sjögren's syndrome: A pilot studyArthritis & Rheumatism, 2001
- Effect of infliximab on sight-threatening panuveitis in Behcet's diseaseThe Lancet, 2001
- Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibodyBone Marrow Transplantation, 2001
- Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialThe Lancet, 2000
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateThe New England Journal of Medicine, 1999
- Infliximab approved for use in Crohn's disease: A report on the fda gi advisory committee conferenceInflammatory Bowel Diseases, 1998